Alexander Perl, MD, is an Associate Professor in the Division of Hematology/Oncology at the Perelman School of Medicine at the University of Pennsylvania and a member of the leukemia program in the Abramson Cancer Center.
Dr Perl graduated from the Mount Sinai School of Medicine in 1997. Following this, he held residence at the UCSF Medical Center in Internal Medicine and completed a Fellowship in Medical Oncology at the Johns Hopkins Hospital.
An active researcher, Dr Perl focuses on molecularly targeted therapeutics for acute leukemia, including FLT3 inhibitors for acute myeloid leukemia (AML), tyrosine kinase inhibitors for Ph-like ALL and inhibitors of oncogenic PI3K/AKT/mTOR signaling. Further, he is interested in preclinical drug screening in cellular and murine xenotransplantation models of acute leukemia. Dr Perl has coordinated important clinical trials on FLT3 inhibitors for AML.